Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;17(1):156-163.e2.
doi: 10.1016/j.cgh.2018.04.043. Epub 2018 Apr 26.

Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease

Mohammad S Siddiqui  1 , Raj Vuppalanchi  1 , Mark L Van Natta  2 , Erin Hallinan  2 , Kris V Kowdley  3 , Manal Abdelmalek  4 , Brent A Neuschwander-Tetri  5 , Rohit Loomba  6 , Srinivasan Dasarathy  7 , Danielle Brandman  8 , Edward Doo  9 , James A Tonascia  2 , David E Kleiner  10 , Naga Chalasani  11 , Arun J Sanyal  1 ; NASH Clinical Research Network
Affiliations

Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease

Mohammad S Siddiqui et al. Clin Gastroenterol Hepatol. 2019 Jan.

Abstract

Background & aims: Vibration-controlled transient elastography (VCTE), which measures liver stiffness, has become an important tool for evaluating patients with nonalcoholic fatty liver disease (NAFLD). We aimed to determine the diagnostic accuracy of VCTE in detection of NAFLD in a multicenter cohort of patients.

Methods: We performed a prospective study of 393 adults with NAFLD who underwent VCTE within 1 year of liver histology analysis (median time, 49 d; interquartile range, 25-78 d), from July 1, 2014, through July 31, 2017. Liver stiffness measurement (LSM) cut-off values for pairwise fibrosis stage and controlled attenuation parameter cut-off values for pairwise steatosis grade were determined using cross-validated area under the receiver operating characteristics curve (AUROC) analyses. Diagnostic statistics were computed at a sensitivity fixed at 90% and a specificity fixed at 90%.

Results: LSM identified patients with advanced fibrosis with an AUROC of 0.83 (95% CI, 0.79- 0.87) and patients with cirrhosis with an AUROC of 0.93 (95% CI, 0.90-0.97). At a fixed sensitivity, a cut-off LSM of 6.5 kPa excluded advanced fibrosis with a negative predictive value of 0.91, and a cut-off LSM of 12.1 kPa excluded cirrhosis with a negative predictive value of 0.99. At a fixed specificity, LSM identified patients with advanced fibrosis with a positive predictive value of 0.71 and patients with cirrhosis with a positive predictive value of 0.41. Controlled attenuation parameter analysis detected steatosis with an AUROC of 0.76 (95% CI, 0.64-0.87). In contrast, the VCTE was less accurate in distinguishing lower fibrosis stages, higher steatosis grades, or the presence of NASH.

Conclusions: In a prospective study of adults with NAFLD, we found VCTE to accurately distinguish advanced vs earlier stages of fibrosis, using liver histology as the reference standard.

Keywords: Controlled Attenuation Parameter; Fibroscan; Fibrosis; NAFLD; Steatosis; VCTE; Vibration Controlled Transient Elastography.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: Mr. Van Natta and Drs. Tonascia, Hallman, Dasarathy, Doo, Brandman, and Kleiner report no conflicts of interests.

Figures

Figure 1
Figure 1
Liver Stiffness Measurement According to Fibrosis Stage
Figure 2
Figure 2
Controlled Attenuation Parameter According to Steatosis Grade
See this image and copyright information in PMC

References

    1. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the united states from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–530.e1. quiz e60. - PubMed
    1. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. - PubMed
    1. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–873. - PubMed
    1. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver Diseases Liver biopsy. Hepatology. 2009;49(3):1017–1044. - PubMed
    1. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898–1906. - PubMed

Publication types